Skip to main content
SpringerLink
Log in

Ľimagerie de contraste ultrasonore pour ľévaluation précoce des thérapeutiques ciblées

  • Chapter
Échographie de contraste

Abstrait

Le phénomène ďangiogenèse, formation de nouveaux vaisseaux à partir de vaisseaux existants, est une étape clé dans le développement des tumeurs. En effet, ľapport des éléments nutritifs se fait uniquement par diffusion passive pour les tumeurs de moins de 2 mm. Au-delà de cette taille, la création ďun réseau de néovaisseaux induit par la sécrétion de substances angiogéniques sécrétées par les cellules tumorales est nécessaire pour que la croissance tumorale se poursuive. La création de ce nouveau réseau vasculaire est également responsable ďune augmentation du potentiel invasif des tumeurs (1, 2, 3).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Folkman J (1971) Tumour angiogenesis: therapeutic implications. N Engl J Med 285: 1182–6

    Article  PubMed  CAS  Google Scholar 

  2. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27–31

    Article  PubMed  CAS  Google Scholar 

  3. Miller JC, Pien HH, Sahani D et al. (2005) Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 97: 172–87

    Article  PubMed  CAS  Google Scholar 

  4. Rehman S, Jayson G (2005) Molecular Imaging of anti-angiogenic agents. The Oncologist 10: 92–103

    Article  PubMed  CAS  Google Scholar 

  5. World, Health Organisation Offset Publication (ed) (1979) WHO Handbook for Reporting Results of Cancer Treatment: Geneva (Switzerland)

    Google Scholar 

  6. Therasse P, Arbuck SG, Eisenhauer EA et al. (2000) New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (3): 205–16

    Article  PubMed  CAS  Google Scholar 

  7. Schwartz L (2004) Conventional and novel techniques for therapeutic response assessment. Radiological Society North America (RSNA). 90th Scientific Assembly and Annual Meeting, Chicago. Proc Radiology 115

    Google Scholar 

  8. Cosgrove D (2003) Angiogenesis imaging. Ultrasound. the British Journal of Radiology 76: S43–S49

    Google Scholar 

  9. Lassau N, Chawi I, Rouffiac V et al. (2004) Interest of colour Doppler ultrasonography to evaluate a new anti-angiogenic treatment with thalidomide in metastatic renal cell carcinoma. Bull Cancer 91 (7–8): 629–35

    PubMed  Google Scholar 

  10. Lassau N, Paturel-Asselin C, Guinebretière JM et al. (1999) New haemodynamic approach to angiogenesis: colour and pulsed Doppler ultrasonography. Invest Radiol 34: 194–8

    Article  PubMed  CAS  Google Scholar 

  11. Asselin C, Lassau N, Guinebretière JM et al. (1999) The in vivo murineinterleukin-12 transfer by the Semliki Forest Virus induces B16 tumour regression through inhibition of tumour blood vessel formation monitored by Doppler ultrasonography. Gene Therapy 4: 606–15

    Article  CAS  Google Scholar 

  12. Escudier B, Lassau N, Couanet D et al. (2002) Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 13 (7): 1029–35

    Article  PubMed  CAS  Google Scholar 

  13. Faivre S, Delbaldo C, Vera K et al. (2006) Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase inhibitor, in patients with cancer. J Clin Oncol 24: 1–11

    Article  CAS  Google Scholar 

  14. Hochedez P, Lassau N, Bonvalot S et al. (2003) [Treatment of local recurrent melanomas by isolated limb perfusion: value of Doppler ultrasonography]. J Radiol 84 (5): 597–603

    PubMed  CAS  Google Scholar 

  15. Lassau N, Koscielny S, Opolon P et al. (2001) Evaluation of contrast-enhanced colour Doppler ultrasound for the quantification of angiogenenis in vivo. Invest Radiol 36: 50–5

    Article  PubMed  CAS  Google Scholar 

  16. Lassau N, Lamuraglia M, Vanel D et al. (2005) Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol 16 (7): 1054–60

    Article  PubMed  CAS  Google Scholar 

  17. Eggermont AM (2005) Evolving imaging technology: contrast-enhanced Doppler ultrasound is early and rapid predictor of tumour response. Ann Oncol 16 (7): 995–6

    Article  PubMed  CAS  Google Scholar 

  18. Lassau N, Lamuraglia M, Leclere J, Rouffiac V (2004) Functional and early evaluation of treatments in oncology: interest of ultrasonographic contrast agents, J Radiol 85: 704–12

    PubMed  CAS  Google Scholar 

  19. Connolly EM, Gaffney E, Reynolds JV (2003) Gastrointestinal stromal tumours. Br J Surg 90: 1178–86

    Article  PubMed  CAS  Google Scholar 

  20. Berman J, O’Leary TJ (2001) Gastrointestinal stromal tumor workshop. Hum Pathol 32: 578–82

    Article  PubMed  CAS  Google Scholar 

  21. Emory TS, Sobin LH, Lukes L (1999) Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 23: 82–7

    Article  PubMed  CAS  Google Scholar 

  22. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052–6

    Article  PubMed  CAS  Google Scholar 

  23. Van Oosterom AT, Judson I, Verweij J et al. (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358: 1421–3

    Article  PubMed  Google Scholar 

  24. Van Oosterom AT, Judson IR, Verweij J et al. (2002) Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38 Suppl 5: S83–S87

    Article  PubMed  Google Scholar 

  25. Verweij J, van Oosterom A, Blay JY et al. (2003) Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39: 2006–11

    Article  PubMed  CAS  Google Scholar 

  26. Chen MY, Bechtold RE, Savage PD (2002) Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GIST) treated with Gleevec (imatinib mesylate). AJR Am J Roentgenol 179: 1059–62

    PubMed  Google Scholar 

  27. Blay JY, Landi B, Bonvalot S et al. (2005) Recommendations for the management of GIST patients. Bull Cancer 92 (10): 907–18

    PubMed  Google Scholar 

  28. Lassau N, Lamuraglia M, Chami L et al. (2006) Gastrointestinal stromal tumours treated with Imatinib: Monitoring response with contrast enhanced ultrasound. AJR In Press

    Google Scholar 

  29. Lassau N, Lamuraglia M, Chami L et al. (2005) Doppler-ultrasonography with perfusion software and contrast medium injection as a tool for early evaluation of gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology, vol. 23, No 16S: 206. 2005 ASCO Annual Meeting Proceedings

    Google Scholar 

  30. Lassau N, Lamuraglia M, Chami L et al. (2005) Doppler-ultrasonography with perfusion software and contrast agent injection as an early evaluation tool of metastatic renal cancers treated with the Raf-Kinase and VEGFR inhibitor: a prospective study. Journal of Clinical Oncology, vol. 23, No 16S: 209. 2005 ASCO Annual Meeting Proceedings

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’échographie Département d’imagerie médicale, Institut Gustave-Desmoulins, 39, rue Camille-Desmoulins, 94805, Villejuif Cedex

    Nathalie Lassau & Pierre Péronneau

  2. Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805, Villejuif Cedex

    Linda Chami

Authors
  1. Nathalie Lassau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Linda Chami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierre Péronneau
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France

About this chapter

Cite this chapter

Lassau, N., Chami, L., Péronneau, P. (2007). Ľimagerie de contraste ultrasonore pour ľévaluation précoce des thérapeutiques ciblées. In: Échographie de contraste. Springer, Paris. https://doi.org/10.1007/978-2-287-33297-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-33297-5_6

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-33294-4

  • Online ISBN: 978-2-287-33297-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation